Search for Stocks /

SRF Ltd Q3 FY26 – ₹3,713 Cr Revenue, ₹433 Cr PAT, EPS ₹14.6: China Dumps, SRF Pumps Capex Like There’s No Tomorrow


1. At a Glance – Blink and You’ll Miss the Drama

SRF Ltd is that one student in class who got bullied by China, ignored by markets, and then casually topped the exam while everyone was still crying about “cyclical downturns.” Q3 FY26 numbers landed with a ₹3,713 Cr revenue and ₹433 Cr PAT, translating into a YoY PAT jump of ~85%, while the stock quietly sits at ₹2,883 wondering why the market still looks unimpressed. Market cap? A solid ₹85,589 Cr. Stock P/E? A spicy 46x, which screams “I am expensive” but whispers “wait till chemicals revive.”

ROCE at 12.3%, ROE 10.4%, debt-to-equity 0.35, and promoter holding a steady 50.26% with zero pledge—basically no late-night margin-call horror stories here. Over the last three months, the stock is down ~8%, which tells you sentiment is still nursing trauma from FY23–FY24.

But here’s the fun part: SRF is spending money like a Bollywood producer who just discovered Netflix—₹12,000–13,000 Cr capex in chemicals, ₹2,000 Cr in packaging films, plus fresh approvals every few months. If patience is an asset, SRF investors are quietly building generational wealth—or ulcers. Curious already? Good. Let’s open the balance sheet and start the roast.


2. Introduction – A Conglomerate With Commitment Issues (But Strong Cash Flows)

SRF Ltd was incorporated in 1970, back when “specialty chemicals” wasn’t even a buzzword—it was just chemistry and courage. Over five decades, SRF has evolved into a multi-legged octopus spanning chemicals, packaging films, technical textiles, and niche fabrics, exporting to 100+ countries and operating 16 manufacturing facilities in India.

Now here’s the irony: SRF is structurally strong but cyclically unlucky. FY22–FY24 was basically SRF vs the world—Chinese dumping, customer destocking, oversupply, and pricing pressure all ganged up like villains in a daily soap. Chemicals revenue fell ~20%, packaging films declined ~6%, and technical textiles slipped ~9%.

Yet, SRF didn’t panic-sell assets or cut R&D. Instead, it doubled down—more patents, more capex, more molecules. That’s either visionary or stubborn. Historically, for SRF,

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →